Mannatech Incorporated (MTEX) and DERMAdoctor LLC. (NASDAQ:DDOC) Contrasting side by side

Mannatech Incorporated (NASDAQ:MTEX) and DERMAdoctor LLC. (NASDAQ:DDOC) compete with each other in the Personal Products sector. We will analyze and contrast their dividends, analyst recommendations, profitability, institutional ownership, risk, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Mannatech Incorporated 175.91M 0.26 6.03M -2.41 0.00
DERMAdoctor LLC. N/A 0.00 N/A -0.12 0.00

Table 1 demonstrates Mannatech Incorporated and DERMAdoctor LLC.’s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 demonstrates the return on assets, return on equity and net margins of Mannatech Incorporated and DERMAdoctor LLC.

Net Margins Return on Equity Return on Assets
Mannatech Incorporated -3.43% -17.3% -8.2%
DERMAdoctor LLC. 0.00% 0% 0%

Dividends

Mannatech Incorporated dividend pay is $1.25 per share with 6.53% dividend yield annually. No dividend is paid out for DERMAdoctor LLC.

Insider & Institutional Ownership

Institutional investors owned 16.6% of Mannatech Incorporated shares and 0% of DERMAdoctor LLC. shares. Mannatech Incorporated’s share owned by insiders are 2.8%.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Mannatech Incorporated 3.36% 18.06% -2.39% -5.21% 37.93% 33.33%
DERMAdoctor LLC. 0% 0% 0% 0% 0% 0%

Mannatech, Incorporated operates as a wellness solution provider. It develops and sells nutritional supplements, topical, skin care and anti-aging products, and weight-management products. The company markets its products through network marketing channel in the Americas, Europe/the Middle East/Africa, and the Asia/Pacific. Mannatech, Incorporated was founded in 1993 and is headquartered in Coppell, Texas.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.